What is the current Human Tuberculosis Vaccine market size?

The Human Tuberculosis Vaccine market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Human Tuberculosis Vaccine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Human Tuberculosis Vaccine market?

Increasing TB cases and growing demand for effective vaccines drive the market.

What are the major challenges facing the Human Tuberculosis Vaccine market?

Limited vaccine efficacy and high development costs are significant challenges.

Which regions are leading the Human Tuberculosis Vaccine market?

Asia Pacific and Africa are leading regions due to high TB prevalence.

Who are the top companies in the Human Tuberculosis Vaccine market?

Sanofi, GSK, and Merck are prominent players in the market.

What are the future opportunities in the Human Tuberculosis Vaccine market?

Emerging markets and innovative vaccine technologies offer future growth opportunities.

How will technology impact the Human Tuberculosis Vaccine market?

Advances in vaccine development and digital health technologies will drive market growth.

What is the current regulatory landscape for the Human Tuberculosis Vaccine market?

Regulatory frameworks support vaccine development and approval processes.

What is the future outlook for the Human Tuberculosis Vaccine market?

The market is expected to grow significantly due to increasing demand and innovation.

Human Tuberculosis Vaccine - Strategic Insights: Analysis 2025 and Forecasts 2033

Human Tuberculosis Vaccine by Application (Pediatrics, Adults), by Types (Intradermal, Percutaneous), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Human Tuberculosis Vaccine Market Size | CAGR 4.2 Forecast 2033

Human Tuberculosis Vaccine - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Human Tuberculosis Vaccine Market Overview

The Human Tuberculosis Vaccine market refers to the global industry involved in the development, production, and distribution of vaccines aimed at preventing tuberculosis in humans. As a crucial sector in the healthcare industry, the Human Tuberculosis Vaccine market size is estimated to be around $533 million in 2025. The growth outlook for this market is promising, with a market forecast indicating significant expansion over the forecast period of 2026-2033. The industry expansion is driven by increasing awareness about tuberculosis, advancements in vaccine technology, and government initiatives to eradicate the disease. Key phrases such as tuberculosis vaccine market trends and vaccine development are crucial in understanding the scope of this market, which encompasses various synonyms including TB vaccines, Bacillus Calmette-Guérin (BCG) vaccines, and new vaccine candidates in clinical trials.

Loading chart…

The Human Tuberculosis Vaccine market is anticipated to grow at a CAGR of around 4.5% from 2026 to 2033, driven by macro drivers such as increasing healthcare expenditure, rising incidence of tuberculosis, and advancements in vaccine technology. Key forces shaping the industry include technology shifts towards more effective and safer vaccines, regulatory approvals for new vaccine candidates, and competitive intensity among market players. The largest region for the Human Tuberculosis Vaccine market is Asia-Pacific, while the fastest-growing region is expected to be Latin America. Overall, the market is poised for significant growth, driven by increasing demand for effective tuberculosis vaccines and ongoing research and development activities.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.67 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Merck; Serum Institute of India; Valneva; Archivel Farma; BIOFABRI (Zendal); Japan BCG Laboratory; GreenSignal Bio Pharma; AJ Vaccines; Taj Pharma India; Biomed Lublin
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Human Tuberculosis Vaccine market is poised for significant growth, driven by increasing awareness and investments in vaccine development. The Human Tuberculosis Vaccine market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in vaccine technology and increasing funding from governments and private organizations are driving the development of more effective and safer vaccines, contributing to the growth of the Human Tuberculosis Vaccine market.

The rising burden of tuberculosis, particularly in low- and middle-income countries, is creating a significant demand for effective vaccines, further fueling the growth of the Human Tuberculosis Vaccine market.

Restraints2 items

Stringent regulatory requirements and complex clinical trial processes are major restraints in the Human Tuberculosis Vaccine market, as they can delay the approval and launch of new vaccines.

High development costs and limited reimbursement for tuberculosis vaccines in some regions are additional challenges that can hinder the growth of the Human Tuberculosis Vaccine market.

Opportunities2 items

Emerging markets, particularly in Asia and Africa, offer significant opportunities for the growth of the Human Tuberculosis Vaccine market due to their large populations and high disease burdens.

Partnerships between vaccine manufacturers, governments, and non-profit organizations can facilitate the development and distribution of affordable and effective tuberculosis vaccines, driving the growth of the Human Tuberculosis Vaccine market.

Challenges2 items

The Human Tuberculosis Vaccine market faces challenges such as vaccine hesitancy and limited awareness about the importance of vaccination in preventing the spread of tuberculosis.

Ensuring a stable and reliable supply chain for tuberculosis vaccines, particularly in resource-limited settings, is a significant challenge that must be addressed to achieve the full potential of the Human Tuberculosis Vaccine market.

Market Segmentation

Loading chart…

The Human Tuberculosis Vaccine market can be segmented based on Application, which includes Preventive and Therapeutic uses. The preventive segment holds a significant share in the Human Tuberculosis Vaccine segmentation, as vaccines are primarily used to prevent the spread of tuberculosis. This segment contributes to the overall market size by providing immunity to individuals, thereby reducing the risk of infection.

Another crucial segment in the Human Tuberculosis Vaccine market is Types, which comprises BCG (Bacille Calmette-Guérin) and New Generation vaccines. The BCG vaccine is the most widely used vaccine, while new generation vaccines are being developed to provide improved protection against tuberculosis. Understanding the Human Tuberculosis Vaccine segmentation is essential for market players to develop targeted strategies and capitalize on emerging opportunities in the market taxonomy.

Human Tuberculosis Vaccine Segmentation Breakdown6 items

Application

Pediatrics

Adults

Types

Intradermal

Percutaneous

Regional Insights

Loading chart…

The Human Tuberculosis Vaccine market growth is anticipated to vary across regions, with the Asia Pacific region being the largest, accounting for approximately 40% of the global market. This region's dominance can be attributed to key drivers such as increasing adoption of tuberculosis vaccines, government policies supporting vaccination programs, and significant investments in healthcare infrastructure.

The fastest-growing region is expected to be Latin America, driven by factors such as rising demographics with a high risk of tuberculosis, improving ecosystem maturity in terms of healthcare services, and growing investments in vaccine research and development. In contrast, North America and Europe are anticipated to experience steady Human Tuberculosis Vaccine market growth, driven by established healthcare systems, ongoing research initiatives, and existing policies supporting vaccine development.

The Middle East & Africa region is also expected to contribute to the global Human Tuberculosis Vaccine market growth, with key drivers including increasing infrastructure development, government initiatives to combat tuberculosis, and a growing awareness of the importance of vaccination. Overall, the regional forecast indicates a diverse landscape, with each region presenting unique opportunities and challenges for the Human Tuberculosis Vaccine market.

Competitive Landscape

The Human Tuberculosis Vaccine market is moderately consolidated, driven by a mix of global players and local/regional companies. The Human Tuberculosis Vaccine competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies rely on pricing and distribution strengths.

Common strategies among key players include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and commoditization. To address these challenges, companies must focus on strategic initiatives that drive growth and profitability.

GlaxoSmithKline: regional expansion

Merck: innovation pipeline

Serum Institute of India: local manufacturing

Valneva: premium pricing

Archivel Farma: OEM tie-ups

BIOFABRI: vertical integration

Key Human Tuberculosis Vaccine Companies11 items

GlaxoSmithKline

Merck

Serum Institute of India

Valneva

Archivel Farma

BIOFABRI (Zendal)

Japan BCG Laboratory

GreenSignal Bio Pharma

AJ Vaccines

Taj Pharma India

Biomed Lublin

Market Ecosystem

The Human Tuberculosis Vaccine ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. The ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where vaccines are manufactured and integrated; and downstream, where vaccines are distributed and administered to end users. The value chain analysis of this ecosystem reveals how value is created and captured at each stage.

Raw material suppliers — provide vaccine components

OEMs / manufacturers — produce vaccines

Technology providers — develop vaccine technologies

Distributors / channel partners — distribute vaccines

Service providers / after-sales — offer vaccine administration services

End users / buyers — receive vaccine administrations

Regulators/standards bodies — set vaccine safety and efficacy standards

The flow of value through the Human Tuberculosis Vaccine ecosystem is influenced by various control points, including regulatory approvals and standards set by regulators and standards bodies. Dependency risks, such as input constraints and approval timelines, can also impact the ecosystem. Switching costs and partnerships between participants can affect the interoperability of vaccine products and services. Furthermore, the ecosystem may differ by region due to varying regulatory requirements, healthcare infrastructure, and disease prevalence.

Recent Industry Insights

The Human Tuberculosis Vaccine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development of new vaccine candidates. Notable mergers and acquisitions have also taken place, enabling companies to expand their vaccine portfolios and strengthen their market presence. Furthermore, several product and technology launches have been announced, showcasing innovative approaches to combating tuberculosis.

Additionally, regulatory changes have been implemented to streamline the approval process for new vaccines, and a shift in consumer awareness has led to increased demand for effective tuberculosis vaccines. The industry has also seen notable funding rounds and expansions, with investors backing promising vaccine candidates and companies scaling up their manufacturing capabilities to meet growing demand. These developments are expected to drive growth in the Human Tuberculosis Vaccine market, shaping the future of tuberculosis prevention and treatment.

Analyst Overview

As the Lead Analyst for this study, my expert view is that the Human Tuberculosis Vaccine market outlook is promising, driven by increasing efforts to combat the disease globally. The market attractiveness is high due to the growing demand for effective vaccines, particularly in regions with high TB prevalence. The competitive intensity is moderate, with several players investing in research and development to improve existing vaccines and develop new ones.

The long-term outlook is positive, with innovation in vaccine technologies and advances in immunology expected to drive growth. However, the demand-supply balance is a concern, with supply chain disruptions and inequitable access to vaccines posing key risk factors. Overall, the Human Tuberculosis Vaccine market is expected to experience steady growth, driven by increasing investments in vaccine development and distribution.

11 items

1. Executive Summary

2. Human Tuberculosis Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Tuberculosis Vaccine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human Tuberculosis Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pediatrics

6.1.2. Adults

6.2. Global Human Tuberculosis Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Intradermal

6.2.2. Percutaneous

6.3. Global Human Tuberculosis Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human Tuberculosis Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Tuberculosis Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Tuberculosis Vaccine Market Competition by Key Manufacturers

8.1. Global Human Tuberculosis Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human Tuberculosis Vaccine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GlaxoSmithKline

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merck

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Serum Institute of India

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Valneva

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Archivel Farma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BIOFABRI (Zendal)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Japan BCG Laboratory

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. GreenSignal Bio Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. AJ Vaccines

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Taj Pharma India

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Biomed Lublin

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Tuberculosis Vaccine Market

Figure 4: Global Human Tuberculosis Vaccine Market: Drivers

Figure 5: Global Human Tuberculosis Vaccine Market: Challenges

Figure 6: Global Human Tuberculosis Vaccine Market: Trends

Figure 7: Global Human Tuberculosis Vaccine Market: Opportunity

Figure 8: Global Human Tuberculosis Vaccine Market: Restraint

Figure 9: Global Human Tuberculosis Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human Tuberculosis Vaccine Market Value (USD Million) By Region

Figure 15: Global Human Tuberculosis Vaccine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human Tuberculosis Vaccine Market Value (USD Million) By Region

Figure 23: Global Human Tuberculosis Vaccine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Tuberculosis Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Tuberculosis Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Tuberculosis Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human Tuberculosis Vaccine Market Value (USD Million) By Region

Table 10: Global Human Tuberculosis Vaccine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human Tuberculosis Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human Tuberculosis Vaccine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human Tuberculosis Vaccine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GlaxoSmithKline Basic Information And Sales Area

Table 31: GlaxoSmithKline. Products Portfolio

Table 32: Merck Basic Information And Sales Area

Table 33: Merck. Products Portfolio

Table 34: Serum Institute of India Basic Information And Sales Area

Table 35: Serum Institute of India. Products Portfolio

Table 36: Valneva Basic Information And Sales Area

Table 37: Valneva. Products Portfolio

Table 38: Archivel Farma Basic Information And Sales Area

Table 39: Archivel Farma. Products Portfolio

Table 40: BIOFABRI (Zendal) Basic Information And Sales Area

Table 41: BIOFABRI (Zendal). Products Portfolio

Table 42: Japan BCG Laboratory Basic Information And Sales Area

Table 43: Japan BCG Laboratory. Products Portfolio

Table 44: GreenSignal Bio Pharma Basic Information And Sales Area

Table 45: GreenSignal Bio Pharma. Products Portfolio

Table 46: AJ Vaccines Basic Information And Sales Area

Table 47: AJ Vaccines. Products Portfolio

Table 48: Taj Pharma India Basic Information And Sales Area

Table 49: Taj Pharma India. Products Portfolio

Table 50: Biomed Lublin Basic Information And Sales Area

Table 51: Biomed Lublin. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Human Tuberculosis Vaccine Market Value (USD Million) By Region

Table 57: Global Human Tuberculosis Vaccine Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human Tuberculosis Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.67 billion
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Merck; Serum Institute of India; Valneva; Archivel Farma; BIOFABRI (Zendal); Japan BCG Laboratory; GreenSignal Bio Pharma; AJ Vaccines; Taj Pharma India; Biomed Lublin
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options